Company: SMNR
Filing Date: 2025-08-08
Form Type: S-4/A
Source: 0001193125-25-177097
Chunk: 768

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-08
Form: S-4/A
Chunk 768
---
 aggregate, paid upon the closing of the IPO. In addition, the underwriters will be entitled to a deferred fee of $ 0.35per Public Unit, or $ 2,887,500in the aggregate, which is included in the accompanying consolidated balance sheets. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. On November 20, 2023, the Company’s Underwriters entered into an Underwriter Letter Agreement, pursuant to which the Company’s Underwriters have agreed to receive 30%, or $ 866,250, of the aggregate $ 2,887,500deferred underwriting commission owed to them upon the closing of the Company’s initial business combination in the form of 86,625shares of shares of common stock of the combined company. Under the terms of the Underwriter Letter Agreement, the shares of common stock of the combined company will be issued at the Closing and the remaining aggregate $ 2,021,250of deferred underwriting compensation owed will remain payable at the Closing in cash under the original terms of the underwriting agreement. NOTE 7 – SHAREHOLDER’S DEFICIT Preference shares– The Company is authorized to issue 1,000,000preference shares with a par value of $ 0.0001per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of December 31, 2024 and December 31, 2023, there wereno preference shares issued and outstanding. Class A Ordinary Shares –The Company is authorized to issue 200,000,000Class A ordinary shares with a par value of $ 0.0001per share. As of December 31, 2024 and December 31, 2023, there were 510,000Class A ordinary shares issued and outstanding, excluding 751,837and 4,537,829Class A ordinary shares subject to possible redemption, respectively. F-28 Class B Ordinary Shares –The Company is authorized to issue 20,000,000Class B ordinary shares with a par value of $ 0.0001per share. As of December 31, 2024 and December 31, 2023, there were 2,062,500Class B ordinary shares issued and outstanding. On May 23, 2022,